Vir Biotechnology Inc stock is traded at $9.96, with a volume of 16,658,906. It is down -17.82% in the last 24 hours and down -6.13% over the past month. Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
Previous Close:
$12.12
Open:
$10.46
24h Volume:
16,658,906
Relative Volume:
4.27
Market Cap:
$1.71B
Revenue:
$68.56M
Net Income/Loss:
-$437.99M
P/E Ratio:
-
EPS:
-$3.16
Net Cash Flow:
-$396.61M
1W Performance:
-18.43%
1M Performance:
-6.13%
6M Performance:
+6.75%
1Y Performance:
+82.08%
1-Day Range:
$9.71$10.70
1-Week Range:
$9.71$14.38
52-Week Range:
$5.32$14.38
Vir Biotechnology Inc Stock (VIR) Company Profile
Name
Vir Biotechnology IncSector
HealthcareIndustry
BiotechnologyPhone
415-906-4324Address
1800 OWENS STREET, SAN FRANCISCO, CA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS